TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company") is pleased to announce that it has closed the final tranche ("Final Tranche") of the offering announced on December 5, 2024 (the "December 5 NR") as amended on January 20, 2025, and based on the better terms announced on March 7, 2025 (the "March 7 NR"). The Company issued 2,420 Debenture Units (as defined in the December 5 NR, as amended by the March 7 NR) for $2,42 ...

Core Viewpoint - Quantum BioPharma Ltd. has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will continue as an advisor to the company [1][3]. Group 1: Appointment Details - Terry Lynch is recognized for founding Save Canadian Mining and has a successful history as an executive in public micro-cap companies [2]. - Lynch is currently the CEO of Power Metallic Mines Inc., which recently secured $50 million in financing [2]. - He is also a co-founder of Cardiol Therapeutics, focusing on cannabidiol for cardiovascular disease treatment [2]. Group 2: Contributions to the Company - CEO Zeeshan Saeed highlighted three key contributions Lynch brings: extensive fundraising experience, biotech investment knowledge, and expertise in stock market manipulation [3]. - Lynch expressed excitement about joining Quantum BioPharma, emphasizing the company's potential and commitment to fairness in capital markets [3]. Group 3: Stock Options - The company granted Lynch 50,000 stock options to acquire Class B Shares at an exercise price of C$9.90, expiring on March 26, 2027 [3]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company is advancing its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership in Celly Nutrition, which includes a royalty agreement on sales from its product unbuzzd™ [4].